companiesCompany
Iambic Therapeutics
AI-discovered oncology molecules in the clinic, including a HER2 inhibitor and a CDK2/4 inhibitor.
IAM1363 (HER2, brain-penetrant) and IAM-H1 entered phase 1 in 2024-25; NeuralPLexer models structure and binding.
AI-discovered oncology molecules in the clinic, including a HER2 inhibitor and a CDK2/4 inhibitor.
IAM1363 (HER2, brain-penetrant) and IAM-H1 entered phase 1 in 2024-25; NeuralPLexer models structure and binding.